Harnessing the innate immune system to combat infectious disease, inflammation, and cancer
StingInn LLC is a clinical-stage biotechnology company harnessing the innate immune system to combat infectious disease, inflammation, and cancer. The company's pipeline is built around the STING (stimulator of interferon genes) signaling pathway, with therapeutics including STING activators (STAVs) for anti-tumor immunotherapy, STING inhibitors for autoimmune and inflammatory disease, and an HTLV-1 vaccine. StingInn has received FDA approval to initiate Phase I clinical trials for leukemia treatment.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2023
Nov 2022
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
